{"id":563714,"date":"2021-09-16T13:00:01","date_gmt":"2021-09-16T13:00:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=563714"},"modified":"2021-09-16T13:00:01","modified_gmt":"2021-09-16T13:00:01","slug":"head-and-neck-squamous-cell-carcinoma-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/head-and-neck-squamous-cell-carcinoma-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working_563714.html","title":{"rendered":"Head and Neck Squamous Cell Carcinoma Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working"},"content":{"rendered":"
\n
\"Head<\/a><\/div>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Head and Neck Squamous Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Head and Neck Squamous Cell Carcinoma, historical and forecasted epidemiology as well as the Head and Neck Squamous Cell Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “Head and Neck Squamous Cell Carcinoma – Market Insights, Epidemiology, and Market Forecast-2030”.<\/a><\/strong><\/p>\n

DelveInsight’s “Head and Neck Squamous Cell Carcinoma – Market Insights, Epidemiology, and Market Forecast-2030″ <\/a><\/strong>report delivers an in-depth understanding of the Head and Neck Squamous Cell Carcinoma, historical and forecasted epidemiology as well as the Head and Neck Squamous Cell Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

\"\"<\/p>\n

Some of the key facts of the Head and Neck Squamous Cell Carcinoma Market Report:<\/strong><\/p>\n

    \n
  1. \n

    According to an Organization, 2014, The annual incidence of head and neck cancers worldwide is more than 550,000 cases with around 300,000 deaths each year. The male to female ratio ranges from 2:1 to 4:1. About 90% of all head and neck cancers are squamous cell carcinomas. <\/p>\n<\/li>\n

  2. \n

    SCC is the most frequent malignant tumor of the head and neck region. HNSCC represents the sixth leading cancer by incidence and there are 500,000 new cases a year worldwide (Kamangar et al., 2006). <\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

      \n
    1. \n

      Head and Neck Squamous Cell Carcinoma  market report covers a descriptive overview and comprehensive insight of the Head and Neck Squamous Cell Carcinoma  Epidemiology and Head and Neck Squamous Cell Carcinoma  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n<\/li>\n

    2. \n

      The Head and Neck Squamous Cell Carcinoma market report provide insights on the current and emerging therapies.<\/p>\n<\/li>\n

    3. \n

      Head and Neck Squamous Cell Carcinoma market report provide a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n<\/li>\n

    4. \n

      The Head and Neck Squamous Cell Carcinoma market report offer an edge that will help in developing business strategies by understanding trends shaping and driving the Head and Neck Squamous Cell Carcinoma market.<\/p>\n<\/li>\n<\/ol>\n

      Got queries? Click here to know more about the Head and Neck Squamous Cell Carcinoma Market Landscape.<\/a><\/strong><\/p>\n

      Head and Neck Squamous Cell Carcinoma Overview<\/strong><\/p>\n

      Head and neck cancer is a term used to define cancer that develops in the mouth (oral cavity), throat, nose, salivary glands, oral cancers, or other areas of the head and neck. Most of these are classified as squamous cases which cover 90% of the disease area. The causes of head and neck cancers are not fully understood. There are certain risk factors that increase the risk of developing the disease such as smoking tobacco, consumption of alcohol, and exposure to the human papillomavirus (HPV) which contributes to the development of at least 90% of squamous cell carcinoma of the head and neck. At least 12% of pharyngeal cancer, 3% of oral cancer, and 30–60% of oropharyngeal carcinoma cases are caused by HPV infection.<\/p>\n

      Head and Neck Squamous Cell Carcinoma Market <\/strong><\/p>\n

      The dynamics of the Head and Neck Squamous Cell Carcinoma market<\/strong> is anticipated to change in the coming years owing to the expected launch of emerging therapies such as Lenvatinib (E7080\/MK-7902) (Merck Sharp & Dohme Corp.), SCT-I10A+Chemo (Sinocelltech Ltd.), Atezolizumab (Hoffmann-La Roche), Ficlatuzumab (AVEO Pharmaceuticals, Inc.), Evorpacept (ALX Oncology) and others during the forecasted period 2021-2030.<\/p>\n

      Learn more by requesting for sample @ Head and Neck Squamous Cell Carcinoma Market Landscape <\/a><\/strong><\/p>\n

      Head and Neck Squamous Cell Carcinoma Pipeline Therapies and Key Companies <\/strong><\/p>\n